http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2605040-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33b011e77b33662b8bf1f2ff2de7b661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6625167799b860081d0032a21148db97
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D223-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351
filingDate 2022-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63af3adf33ab92a77260f6ddc2c7a2fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27529d542a299a0f16791bd2c55166df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4319e0d992de7e29950bb95a1a4751f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17201d0af3b104c6f6dbaa6df0cdca1e
publicationDate 2022-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-2605040-A
titleOfInvention Inhibitors of influenza viral entry
abstract Vaccination is the most prevalent prophylactic means for controlling seasonal influenza infections. However, an effective vaccine usually takes at least 6 months to develop for the circulating strains. Therefore, new therapeutic options are needed for acute treatment of influenza infections to control this virus and prevent epidemic/pandemic situations from developing. Described herein are fast-acting, orally active acylated amino-substituted heterocyclyl compounds effective to control this virus. In one aspect, described herein is a method of treating an influenza infection in a subject comprising administering to the subject the compounds described herein.
priorityDate 2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019004421-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65028
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60855
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534777
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393640
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534785
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457461622
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154234
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590953

Total number of triples: 45.